News
Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can help with reducing the burden of trial participation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback